1. Home
  2. TYRA vs ESTA Comparison

TYRA vs ESTA Comparison

Compare TYRA & ESTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$31.06

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Establishment Labs Holdings Inc.

ESTA

Establishment Labs Holdings Inc.

HOLD

Current Price

$93.42

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
ESTA
Founded
2018
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
TYRA
ESTA
Price
$31.06
$93.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
7
Target Price
$47.50
$86.86
AVG Volume (30 Days)
923.4K
724.3K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.67
EPS
N/A
N/A
Revenue
N/A
$61,208,000.00
Revenue This Year
N/A
$28.05
Revenue Next Year
N/A
$26.21
P/E Ratio
N/A
N/A
Revenue Growth
N/A
76.49
52 Week Low
$9.96
$33.35
52 Week High
$40.65
$93.12

Technical Indicators

Market Signals
Indicator
TYRA
ESTA
Relative Strength Index (RSI) 49.81 68.09
Support Level $28.92 $63.71
Resistance Level $31.57 N/A
Average True Range (ATR) 1.87 3.58
MACD 0.05 -0.10
Stochastic Oscillator 47.47 92.68

Price Performance

Historical Comparison
TYRA
ESTA

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About ESTA Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

Share on Social Networks: